[Role of allopurinol and rofecoxib in agranulocytosis and acute tubular necrosis]. / Implicación de alopurinol y rofecoxib en agranulocitosis y necrosis tubular aguda.
Farm Hosp
; 27(5): 317-22, 2003.
Article
em Es
| MEDLINE
| ID: mdl-14576922
ABSTRACT
OBJECTIVE:
To report the case of a patient who developed a life-threatening agranulocytosis and acute tubular necrosis after the administration of allopurinol and rofecoxib. CASE REPORT After minor surgery, a 70-year-old male underwent a routine blood test which encountered anemia, leucopenia, neutropenia, thrombopenia, and altered creatinine levels. Both marrow and renal biopsies were performed, yielding the followingresults:
acute tubular necrosis and agranulocytosis in the recovery stage. One month and a half before the aforementioned surgery a routine blood test had been performed, which showed normal values. The patient had then received allopurinol 100 mg/day for around 2 months, and rofecoxib 2.5 mg/day for 14 days.DISCUSSION:
After ruling out other possible causes, a diagnosis of iatrogenically induced agranulocytosis and acute tubular necrosis was reached. We used a (modified) Karch-Lasagna algorithm with both drugs, and found the following imputability values possible for rofecoxib and probable for allopurinol. In view of the widespread use of rofecoxib and COX-2 inhibitors, despite their recent availability, and of their potential role in the severe adverse effects discussed, healthcare professionals must be on the alert for the development of symptoms suggesting said or other adverse effects.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Alopurinol
/
Inibidores de Ciclo-Oxigenase
/
Agranulocitose
/
Inibidores Enzimáticos
/
Necrose Tubular Aguda
/
Lactonas
Limite:
Aged
/
Humans
/
Male
Idioma:
Es
Revista:
Farm Hosp
Assunto da revista:
FARMACIA
/
HOSPITAIS
Ano de publicação:
2003
Tipo de documento:
Article
País de publicação:
ES
/
ESPANHA
/
ESPAÑA
/
SPAIN